Pain after total hip replacement
Conditions
Interventions
Ropivacaine + normal saline group :Local infiltration injection of ropivacaine + normal saline at the incision site
Ropivacaine + dexamethasone group:Local infiltration injection of ropivacaine and dexamethasone at the incision site
Ropivacaine + ascorbic acid group:Local infiltration injection of ropivacaine + ascorbic acid at the incision site
Sponsors
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Eligibility
Sex/Gender
All
Age
30 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. After fully informing about the benefits and risks of the trial, they agreed to participate in the trial and voluntarily signed the informed consent form; 2. Age between 30 and 70 years old; 3. Have obvious hip joint pain accompanied by movement impairment, and the imaging results indicate end-stage hip joint disease, requiring a first-time total hip replacement; 4. Conservative treatment has been ineffective for at least 3 months, and the conservative treatment includes physical therapy, pain medication treatment and joint cavity injection; 5. American Society of Anesthesiologists Physical Status Classification (ASA) is level I-II; 6. Can independently use the patient-controlled analgesia pump (PCA).
Exclusion criteria
Exclusion criteria: 1. Patients with autoimmune diseases (rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, etc.); 2. Patients with hip joint deformity or stiffness, patients undergoing hip joint revision; 3. Known allergies to the test drugs (dexamethasone, ascorbic acid, ropivacaine, Celebrex, diclofenac sodium); 4. Ischemic heart disease, bradycardia (heart rate 35), liver and kidney dysfunction); 6. Patients who have been taking hormones or sedative analgesic drugs for a long time; 7. Active or chronic systemic infections throughout the body, such as AIDS, syphilis, hepatitis, etc.; 8. Severe mental disorders (psychosis, severe emotional disorders or schizophrenia); 9. Recent or past history of alcohol, opioid or anesthetic drug dependence; 10. Pregnant or preparing to become pregnant; 11. Unable to operate the PCA device or unable to answer the pain questionnaire due to mental or physical reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The total dosage of opioid drugs used in patient-controlled analgesia (PCA) within 48 hours after the operation;The NRS pain scores at 12 hours and 24 hours after the operation; | — |
Secondary
| Measure | Time frame |
|---|---|
| The time from the end of the surgery to the first press of the PCA analgesic pump;Postoperative Harris score of patients undergoing hip joint replacement;Inflammatory indicators during the perioperative period (C-reactive protein, erythrocyte sedimentation rate, interleukin-6); | — |
Countries
China
Contacts
Public ContactLi Wenkai
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Outcome results
None listed